-$0.76 EPS Expected for Nevro Corp (NYSE:NVRO) This Quarter

Wall Street analysts expect Nevro Corp (NYSE:NVRO) to report earnings of ($0.76) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Nevro’s earnings, with the lowest EPS estimate coming in at ($0.96) and the highest estimate coming in at ($0.56). Nevro posted earnings per share of ($0.32) in the same quarter last year, which would indicate a negative year over year growth rate of 137.5%. The company is expected to announce its next quarterly earnings report on Thursday, February 20th.

On average, analysts expect that Nevro will report full year earnings of ($3.75) per share for the current fiscal year, with EPS estimates ranging from ($4.26) to ($3.49). For the next financial year, analysts expect that the company will post earnings of ($2.96) per share, with EPS estimates ranging from ($3.78) to ($1.41). Zacks’ EPS calculations are an average based on a survey of research firms that follow Nevro.

Nevro (NYSE:NVRO) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.27. The firm had revenue of $100.16 million during the quarter, compared to analyst estimates of $92.27 million. Nevro had a negative return on equity of 41.07% and a negative net margin of 24.51%. Nevro’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.37) earnings per share.

A number of brokerages have recently issued reports on NVRO. Leerink Swann set a $98.00 target price on shares of Nevro and gave the stock a “buy” rating in a research report on Friday, August 23rd. ValuEngine downgraded Nevro from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America raised their target price on Nevro from $70.00 to $74.00 and gave the company a “buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their target price on Nevro from $62.00 to $80.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Zacks Investment Research raised Nevro from a “sell” rating to a “hold” rating and set a $67.00 target price for the company in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company. Nevro currently has an average rating of “Hold” and a consensus price target of $86.83.

Shares of NVRO traded up $2.21 during mid-day trading on Thursday, reaching $105.59. 798,622 shares of the company’s stock were exchanged, compared to its average volume of 519,500. The company has a debt-to-equity ratio of 0.89, a current ratio of 6.05 and a quick ratio of 4.66. The stock has a market capitalization of $2.69 billion, a PE ratio of -64.38 and a beta of 0.21. The business’s fifty day simple moving average is $85.49 and its 200-day simple moving average is $72.60. Nevro has a 52-week low of $34.75 and a 52-week high of $108.20.

In other Nevro news, VP Doug Alleavitch sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $100.00, for a total value of $100,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Quest Capital Management Inc. ADV acquired a new position in Nevro in the 3rd quarter valued at about $26,000. Quantamental Technologies LLC purchased a new stake in Nevro in the 2nd quarter valued at about $75,000. Atria Investments LLC purchased a new stake in Nevro in the 2nd quarter valued at about $267,000. Creative Planning purchased a new stake in Nevro in the 3rd quarter valued at about $224,000. Finally, Prudential Financial Inc. purchased a new stake in Nevro in the 2nd quarter valued at about $202,000.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

See Also: What is a growth and income fund?

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.